Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Establishment of a simple and efficient platform for car-t cell generation and expansion: from lentiviral production to in vivo studies

9 Oct 2019

Abstract excerpt

INTRODUCTION: Adoptive transfer of T cells expressing a CD19-specific chimeric antigen receptor (CAR) has shown impressive response rates for the treatment of CD19 + B-cell malignancies in numerous clinical trials. The CAR molecule, which recognizes cell-surface tumor-associated antigen independently of human leukocyte antigen (HLA), is composed by one or more signaling molecules to activate genetically modified...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immune Cell Function and Interaction
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31676276
DOI: 10.1016/j.htct.2019.06.007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Establishment of a simple and efficient platform for car-t cell generation and expansion: from lentiviral production to in vivo studiesPMID 31676276Read ↗

Production of CAR T-cells by GMP-grade lentiviral vectors: latest advances and future prospectsSemantic proximity Read ↗

CAR therapy: the CD19 paradigmSemantic proximity Read ↗

Manufacturing CD20/CD19-targeted iCasp9 regulatable CAR-T <sub>SCM</sub> cells using <i>qCART</i> , the <i>Quantum pBac</i> -based CAR-T systemSemantic proximity Read ↗

Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-hodgkin Lymphoma.Semantic proximity Read ↗

In Vivo Generation of CAR T Cells Selectively in Human CD4+ LymphocytesSemantic proximity Read ↗

In vivo generation of human CD19‐CAR T cells results in B‐cell depletion and signs of cytokine release syndromeSemantic proximity Read ↗

Chimeric Antigen Receptors: A Paradigm Shift in ImmunotherapySemantic proximity Read ↗

Lentiviral Vectors for CAR-T and Other Cell Therapy Products: A Microbiological and Biosafety PerspectiveSemantic proximity Read ↗

Lentiviral particle-mediated generation of in-vivo CAR-T cells for treating refractory B-cell lymphomaSemantic proximity Read ↗

Generation and GMP scale-up of human CAR-T cells using non-viral Sleeping Beauty transposons for B cell malignancesSemantic proximity Read ↗

Lentivirus for CAR-T and Other Cell Therapy Products: A Microbiological and Biosafety PerspectiveSemantic proximity Read ↗

Anti-CD19 CARs displayed at the surface of lentiviral vector particles promote transduction of target-expressing cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.